Sobre 15 señales de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Browse the full record of transactions filed by Whitmore Bradford T, Director. Director active across 4 companies, notably Ultralife CORP. Aggregated, 40 reports have been logged. Split: 36 buys · 2 sells. Total volume traded: €42.9m. History available since 7 May 2021. The latest transaction was disclosed on 12 March 2026 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Whitmore Bradford T
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
300.488 títulos@ 1,1002 US$0.5% de su flujoCommon StockSEC:0000933430-22-000011:0
Salida canónica: 15 mar 2023 (T+90)
25 de 40 declaraciones
About Whitmore Bradford T
WHITMORE BRADFORD T is Director at Ultralife CORP. The record shows 40 filings in total, and the sampled recent filings run from 2016-02-10 to 2026-03-16, with buys of EUR 13652990 and sells of EUR 29290545. The largest transactions in that sample include NANOPHASE TECHNOLOGIES Corp, SOLESENCE, INC. and Clearside Biomedical, Inc., with a sale of EUR 28695387.22003782 on 2021-12-23 at NANOPHASE TECHNOLOGIES Corp and a buy of EUR 9228030.039998429 on 2025-06-02 at SOLESENCE, INC.